The European Commission (EC) accepts for review BeiGene’s (NASDAQ:BGNE) marketing application seeking approval of BTK inhibitor Brukinsa (zanubrutinib) for the treatment of Waldenström’s macroglobulinemia (WM), a rare cancer of the bone marrow and lymphatic tissues characterized by abnormally large numbers of B lymphocytes.
The specific indication is for WM patients who
have received at least one prior line of therapy or in a first-line
setting in patients who are unsuitable for chemo.
https://seekingalpha.com/news/3584085-ec-accepts-beigene-application-for-brukinsa-for-rare-blood-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.